<SEC-DOCUMENT>0001193125-18-005154.txt : 20180108
<SEC-HEADER>0001193125-18-005154.hdr.sgml : 20180108
<ACCEPTANCE-DATETIME>20180108083356
ACCESSION NUMBER:		0001193125-18-005154
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180108
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180108
DATE AS OF CHANGE:		20180108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CERUS CORP
		CENTRAL INDEX KEY:			0001020214
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				680262011
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21937
		FILM NUMBER:		18514969

	BUSINESS ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520
		BUSINESS PHONE:		9252886000

	MAIL ADDRESS:	
		STREET 1:		2550 STANWELL DRIVE
		STREET 2:		STE 300
		CITY:			CONCORD
		STATE:			CA
		ZIP:			94520

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CERUS TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19960731
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d521973d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of report (Date of earliest event reported): January&nbsp;8, 2018</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CERUS CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter)</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-21937</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">68-0262011</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2550 Stanwell Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Concord, California</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94520</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s Telephone Number, Including Area Code (925)
<FONT STYLE="white-space:nowrap">288-6000</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or Former Address, if Changed Since Last Report)</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (<I>see</I> General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communication pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communication pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 (17 CFR <FONT STYLE="white-space:nowrap">&#167;240.12b-2).</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:pmingliu"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></FONT><FONT
STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;<FONT STYLE="font-family:pmingliu"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2018, Cerus
Corporation (the &#147;Company&#148;) announced its preliminary product revenue results for the fourth quarter and fiscal year ended December&nbsp;31, 2017. A copy of the Company&#146;s press release, entitled &#147;Cerus Corporation Announces
Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017,&#148; is furnished pursuant to Item 2.02 as Exhibit&nbsp;99.1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this report, including the exhibit hereto, shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of
the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section&nbsp;11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be
incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The following exhibit is furnished with this report: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">99.1</TD>
<TD ALIGN="left" VALIGN="top"><A HREF="d521973dex991.htm">Press release, dated January&nbsp;8, 2018, entitled &#147;Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017.&#148; </A> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">CERUS CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">Dated: January&nbsp;8, 2018</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:10pt">By:</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:10pt">/s/ Kevin D. Green</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin D. Green</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vice President, Finance and
Chief Financial Officer</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d521973dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g521973g56a67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Record preliminary product revenue reported along with expected strong 2018 growth </I></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONCORD, CA, January&nbsp;8, 2018 &#150; Cerus Corporation (NASDAQ: CERS) today announced unaudited preliminary product revenue for the fourth quarter and
full year 2017 and provided 2018 product revenue guidance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus&#146; unaudited preliminary product revenue for the fourth quarter of 2017 was
$16.2&nbsp;million, an increase of 60% compared to fourth quarter of 2016. Driving the growth was an increase in global demand for INTERCEPT platelet kits of more than 100%. Preliminary results in the quarter reflect the initial rollout for broad
use of the INTERCEPT Blood Systems for platelets in France. Based on the fourth quarter unaudited preliminary product revenue, the Company expects full year 2017 product revenue to be $43.6&nbsp;million, representing an increase of 17% compared to
prior year product revenue. The preliminary product revenue results reported have not been audited and are subject to change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Preliminary fourth
quarter sales results exceeded our expectations and would mark the highest quarterly product revenue ever reported by Cerus. We finished 2017 on a solid note and look forward to building on this success throughout 2018,&#148; said William
&#145;Obi&#146; Greenman, Cerus&#146; president and chief executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;As we enter 2018, we are excited to expand patient access to INTERCEPT
across the EMEA markets, to continue to drive U.S. product adoption, and to expand our INTERCEPT commercial portfolio with the anticipated CE Mark submission for red cells and the&nbsp;progress on our planned cryoprecipitate PMA supplement
submission. We anticipate 2018 product revenue to be in the range of $51&nbsp;million to $53&nbsp;million, representing 17 to 22% growth,&#148; continued Greenman. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus will provide complete fourth quarter and full year 2017 financial results and host a call in early March. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT CERUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk
of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to
inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System
for&nbsp;both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See
http://www.cerus.com for information about Cerus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except for the historical
statements contained herein, this press release contains forward-looking statements concerning Cerus&#146; products, prospects and expected results, including statements relating to Cerus&#146; expected product revenue for the fourth quarter and
year ended December&nbsp;31, 2017; Cerus&#146; expectation of expanding patient access to INTERCEPT across the EMEA markets and continuing to drive U.S. product adoption; Cerus&#145; planned INTERCEPT red blood cell CE Mark submission; anticipated
progress with Cerus&#146; planned cryoprecipitate PMA supplement submission; Cerus&#146; anticipated 2018 annual product revenue; and other statements that are not historical fact. Actual results could differ materially from these forward-looking
statements as a result of certain factors, including, without limitation: risks related to preliminary financial results, including the risks (a)&nbsp;that the preliminary financial results reported in this press release only reflect information
available to Cerus at this time and may differ from actual results, (b)&nbsp;that the preliminary financial results reported in this press release have not been reviewed or audited by Cerus&#146; independent registered public accounting firm, which
independent registered public accounting firm has not expressed any opinion or any other form of assurance with respect to such preliminary financial results, and (c)&nbsp;that there can be no assurance that Cerus&#146; actual financial results for
the periods presented in this press release will not differ from the preliminary financial results presented in this press release and such differences could be material; risks associated with the commercialization and market acceptance of, and
customer demand for, the INTERCEPT Blood System, including the risks that&nbsp;Cerus&nbsp;may not (a)&nbsp;meet its annual revenue guidance for 2018, (b) grow sales in its EMEA and other major international markets, and/or (c)&nbsp;realize
meaningful revenue contributions from U.S. customers in the near term or at all, particularly since&nbsp;Cerus&nbsp;cannot guarantee the volume or timing of commercial purchases, if any, that its U.S. customers may make under Cerus&#146; commercial
agreements with these customers; risks associated with Cerus&#146; lack of commercialization experience in&nbsp;the United States&nbsp;and its ability to develop and maintain an effective and qualified U.S.-based commercial organization, as well as
the resulting uncertainty of its ability to achieve market acceptance of and otherwise successfully commercialize the INTERCEPT Blood&nbsp;System for platelets and plasma in&nbsp;the United States, including as a result of licensure requirements
that must be satisfied by U.S. customers prior to their engaging in interstate transport of blood components processed using the INTERCEPT Blood System; risks related to Fresenius Kabi&#146;s efforts to assure an uninterrupted supply of platelet
additive solution (PAS); risks related to how any future PAS supply disruption could affect </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
INTERCEPT&#146;s acceptance in the marketplace; risks related to how any future PAS supply disruption might affect current commercial contracts; risks related to Cerus&#146; ability to
commercialize the INTERCEPT Blood System in&nbsp;the United States&nbsp;without infringing on the intellectual property rights of others; risks related to Cerus&#146; ability to demonstrate to the transfusion medicine community and other health care
constituencies that pathogen reduction and the INTERCEPT Blood System is safe, effective and economical; the uncertain and time-consuming development and regulatory process, including the risks (a)&nbsp;that&nbsp;Cerus&nbsp;may be unable to comply
with the FDA&#146;s post-approval requirements for the INTERCEPT platelet and plasma systems, including by successfully completing required post-approval studies, which could result in a loss of U.S. marketing approval for the INTERCEPT platelet
and/or plasma systems, (b)&nbsp;related to Cerus&#146; ability to expand the label claims and product configurations for the INTERCEPT platelet and plasma systems in&nbsp;the United States, which will require additional regulatory approvals,
(c)&nbsp;related to unanticipated difficulties in meeting the planned cryoprecipitate PMA supplement requirements, including the risk that the FDA could require additional clinical data to support potential approval, (d)&nbsp;that Cerus&#146; blood
center customers may be unable to obtain approvals by the&nbsp;FDA&nbsp;of BLAs they have submitted to the&nbsp;FDA&nbsp;allowing for interstate transport of blood components processed using the INTERCEPT Blood System in a timely manner or at all,
which could significantly delay or preclude Cerus&#146; ability to successfully commercialize the INTERCEPT Blood System to those customers for the portion of their business involved in interstate commerce, and (e)&nbsp;that Cerus may be unable to
file for CE Mark approval of the red blood cell system in&nbsp;Europe&nbsp;in the anticipated timeframe or at all, and even if filed, Cerus&nbsp;may be unable to obtain CE Mark approval, or any other regulatory approvals, of the red blood cell
system in a timely manner or at all; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or weakening economic conditions in the markets
where&nbsp;Cerus&nbsp;sells its products; Cerus&#146; reliance on third parties to market, sell, distribute and maintain its products; Cerus&#146; ability to maintain an effective manufacturing supply chain, including the ability of its
manufacturers to comply with extensive&nbsp;FDA&nbsp;and foreign regulatory agency requirements; the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for&nbsp;Cerus&nbsp;to produce, market and
distribute its products; risks related to future opportunities and plans, including the uncertainty of future revenues and other financial performance and results, as well as other risks detailed in Cerus&#146; filings with the&nbsp;Securities and
Exchange Commission, including Cerus&#146; Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarter ended&nbsp;September 30, 2017, filed with the&nbsp;SEC&nbsp;on&nbsp;November&nbsp;3, 2017.&nbsp;In addition, the
preliminary financial results reported in this press release should not be viewed as a substitute for full financial statements prepared in accordance with GAAP and are not necessarily indicative of the results to be achieved for any future periods.
Cerus&nbsp;disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contact: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim Lee &#150; Investor Relations Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cerus Corporation
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">925-288-6137</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g521973g56a67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521973g56a67.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0 Z17AI9@  34T *@    @  U$0  $
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0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
